Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 139
Filter
1.
Curbing the climb in cancer incidence.
The Lancet Oncology.
Lancet Oncol ; 25(5): 529, 2024 May.
Article in English | MEDLINE | ID: mdl-38697150

Subject(s)
Neoplasms , Humans , Incidence , Neoplasms/epidemiology
2.
Putting patient safety first: a global imperative.
The Lancet Oncology.
Lancet Oncol ; 25(6): 683, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38821077

Subject(s)
Global Health , Patient Safety , Humans , Neoplasms/epidemiology
3.
Intellectual and developmental disabilities-an under-recognised driver of cancer mortality.
The Lancet Oncology.
Lancet Oncol ; 25(4): 411, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38547885

Subject(s)
Intellectual Disability , Neoplasms , Child , Humans , Developmental Disabilities/diagnosis , Developmental Disabilities/epidemiology
4.
Safe and effective cancer care: how long must we wait?
The Lancet Oncology.
Lancet Oncol ; 25(3): 265, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38423038

Subject(s)
Neoplasms , Humans , Neoplasms/therapy , Waiting Lists , Time Factors
5.
Immunotherapy: balancing the risks and benefits.
The Lancet Oncology.
Lancet Oncol ; 25(2): 147, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38301683

Subject(s)
Immunotherapy , Humans , Risk Assessment , Immunotherapy/adverse effects
6.
Commercial determinants of cancer.
The Lancet Oncology.
Lancet Oncol ; 25(1): 1, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38181802
7.
Expression of concern-Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
The Editors Of The Lancet Oncology.
Lancet Oncol ; 25(2): e42, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38142701
8.
Breast cancer screening: one size does not fit all.
The Lancet Oncology.
Lancet Oncol ; 24(12): 1287, 2023 Dec.
Article in English | MEDLINE | ID: mdl-38039986

Subject(s)
Breast Neoplasms , Colorectal Neoplasms , Humans , Female , Breast Neoplasms/diagnosis , Early Detection of Cancer , Mass Screening , Occult Blood , Colonoscopy
9.
Cancer caught in the crossfire.
The Lancet Oncology.
Lancet Oncol ; 24(11): 1157, 2023 11.
Article in English | MEDLINE | ID: mdl-37858330
10.
Patient first; person first.
The Lancet Oncology.
Lancet Oncol ; 24(10): 1053, 2023 10.
Article in English | MEDLINE | ID: mdl-37797625
11.
Avoidable mortality in the UK unlikely to change soon.
The Lancet Oncology.
Lancet Oncol ; 24(9): 945, 2023 09.
Article in English | MEDLINE | ID: mdl-37657464

Subject(s)
Mortality , Humans , United Kingdom/epidemiology
12.
Climate change and skin cancer: urgent call for action.
The Lancet Oncology.
Lancet Oncol ; 24(8): 823, 2023 08.
Article in English | MEDLINE | ID: mdl-37541266

Subject(s)
Climate Change , Skin Neoplasms , Humans , Skin Neoplasms/epidemiology , Skin Neoplasms/etiology , Skin Neoplasms/prevention & control
13.
Meeting the need for germline testing.
The Lancet Oncology.
Lancet Oncol ; 24(7): 709, 2023 07.
Article in English | MEDLINE | ID: mdl-37414006

Subject(s)
Genetic Predisposition to Disease , Genetic Testing , Humans , Germ-Line Mutation
14.
Can artificial intelligence improve cancer care?
The Lancet Oncology.
Lancet Oncol ; 24(6): 577, 2023 06.
Article in English | MEDLINE | ID: mdl-37269835

Subject(s)
Artificial Intelligence , Neoplasms , Humans , Algorithms , Neoplasms/diagnosis , Neoplasms/therapy
15.
Access to cancer medicines in the UK.
The Lancet Oncology.
Lancet Oncol ; 24(5): 415, 2023 05.
Article in English | MEDLINE | ID: mdl-37142364

Subject(s)
Health Services Accessibility , Neoplasms , Humans , Neoplasms/drug therapy , Neoplasms/epidemiology , United Kingdom
16.
Cancer no longer a priority for England?
The Lancet Oncology.
Lancet Oncol ; 24(3): 195, 2023 03.
Article in English | MEDLINE | ID: mdl-37052961

Subject(s)
Neoplasms , State Medicine , Humans , England/epidemiology , Neoplasms/epidemiology , Neoplasms/therapy
17.
Quality control and childhood cancer medicines.
The Lancet Oncology.
Lancet Oncol ; 24(3): 195, 2023 03.
Article in English | MEDLINE | ID: mdl-37052962

Subject(s)
Neoplasms , Humans , Child , Neoplasms/drug therapy , Quality Control
18.
Expression of concern-Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
The Editors Of The Lancet Oncology.
Lancet Oncol ; 24(4): e145, 2023 04.
Article in English | MEDLINE | ID: mdl-36931286
19.
Equitable cancer care at any age.
The Lancet Oncology.
Lancet Oncol ; 24(4): 307, 2023 04.
Article in English | MEDLINE | ID: mdl-36990603

Subject(s)
Neoplasms , Humans , Neoplasms/epidemiology , Neoplasms/therapy , Health Services Accessibility , Healthcare Disparities
20.
National crises and cancer control: challenges for Latin America and beyond.
The Lancet Oncology.
Lancet Oncol ; 24(2): 117, 2023 02.
Article in English | MEDLINE | ID: mdl-36725141

Subject(s)
Neoplasms , Humans , Latin America/epidemiology , Neoplasms/epidemiology , Neoplasms/prevention & control
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL